HIV Infections Clinical Trial
Official title:
Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
Verified date | March 2017 |
Source | Hospital Clinic of Barcelona |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
24 healthy male and female volunteers who are at low risk of HIV infection and entered into
the RISVAC02 study and were randomly allocated to receive 3 intramuscular injections of
MVA-B at weeks 0, 4 and 16 will receive a boosting dose 4 years thereafter.
Participants will attend one of two clinical centres on at least 5 occasions over 16 weeks.
These visits will comprise:
- Screening
- Trial entry and boosting immunisation
- Early follow-up after immunisation
- Follow-up x 2 including the final visit Participants will have blood and urine
collected, and receive 1 immunisation. They will be counselled prior to and following a
HIV test, and given health education on prevention of sexually transmitted infections
including HIV. T
The two centres which participate are:
- Hospital Clinic, Barcelona and
- Hospital Gregorio Marañón, Madrid The primary objective is to explore the safety and
immunogenicity of MVA-B.
Status | Completed |
Enrollment | 24 |
Est. completion date | September 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - male or female - age between 18 and 55 years on the day of screening - available for follow-up for the duration of the study (52 weeks from screening) - able to give written informed consent - at low risk of HIV and willing to remain so for the duration of the study low risk of HIV infection defined as: no history of injecting drug use in the previous ten years no gonorrhoea or syphilis in the last six months no high risk partner (e.g. injecting drug use, HIV positive partner) either currently or within the past six months no unprotected anal intercourse in the last six months no unprotected vaginal intercourse outside a relationship with a regular known/presumed HIV negative partner in the last six months - willing to undergo a HIV test - willing to undergo a genital infection screen - if heterosexually active female, using an effective method of contraception with partner (combined oral contraceptive pill; injectable contraceptive; IUCD; consistent record with condoms if using these; physiological or anatomical sterility in self or partner) from 14 days prior to the first vaccination until 4 months after the last, and willing to undergo urine pregnancy tests prior to each vaccination - if heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination Exclusion Criteria: - positive for hepatitis B surface antigen, hepatitis C antibody, antibody responses to vaccinia or serology indicating active syphilis requiring treatment - pregnant or lactating - clinically relevant abnormality on history or examination including history of grand-mal epilepsy, severe eczema, immunodeficiency or use of immunosuppressives in preceding 3 months - receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of enrolment - receipt of blood products or immunoglobin within 4 months of screening - participation in another trial of a medicinal product, completed less than 30 days prior to enrolment - history of severe local or general reaction to vaccination defined as local: extensive, indurated redness and swelling involving most of the front-lateral thigh or the major circumference of the arm, not resolving within 72 hours general: fever >= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal - HIV 1/2 positive or indeterminate on screening - positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating active syphilis requiring treatment - grade 1 routine laboratory parameters - unlikely to comply with protocol |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clínic i Provincial de Barcelona | Barcelona | Catalunya |
Spain | Hospital Universitario Gregorio Marañón | Madrid |
Lead Sponsor | Collaborator |
---|---|
Hospital Clinic of Barcelona |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Local adverse event | Grade 3 or above local adverse event (pain, cutaneous reactions including induration) | 12 weeks | |
Primary | Grade 3 or above systemic adverse event | Grade 3 or above systemic adverse event (temperature, chills, headache, nausea, vomiting, malaise, and myalgia) | 12 weeks | |
Primary | Grade 3 or above other clinical or laboratory adverse event | Grade 3 or above other clinical or laboratory adverse event confirmed at examination or on repeat testing respectively | 12 weeks | |
Primary | Event attributable to vaccine leading to discontinuation | Any event attributable to vaccine leading to discontinuation of the immunisation regimen | 12 weeks | |
Primary | Primary immunogenicity parameters | The primary immunogenicity parameters will be quantitative or present/absent, and are cellular responses - CD8/CD4+ T cell responses (ELISPOT) at week 2, 4 and 12 following the immunisations | 12 weeks | |
Secondary | All grade 1 and 2 adverse events | 28 days of vaccination | ||
Secondary | Antibody responses | binding titration to the construct MVAB binding titration to and neutralisation of vaccinia |
12 weeks | |
Secondary | cellular responses | CD8/CD4+ T cell responses (ELISPOT) at week 0 intracellular cytokine analysis at week 0, 2, 4 and 12 |
12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |